Harmos Horton Lusk is advising KRX listed Lunit Inc. on the acquisition of ASX listed Volpara Health Technologies Limited by way of a New Zealand scheme of arrangement. The proposed scheme values Volpara at AU$295.7 million and is expected to be implemented in Q2 of 2024, subject to the satisfaction of various conditions, including shareholder, New Zealand High Court and New Zealand Overseas Investment Office approvals.
The firm is the New Zealand legal adviser to Lunit, including advising on transaction structuring, negotiation of definitive documents, and regulatory approvals. Lunit is also advised by Baker & McKenzie, as Australian and international counsel, and by Evercore and Luminis as financial advisers.
Volpara is a global leader in software for the early detection of breast cancer. Lunit is a deep learning-based medical AI company committed to harnessing AI to ensure accurate diagnosis and optimal treatment for cancer patients. The transaction is intended to accelerate Volpara's ability to serve its purpose of saving families from cancer.
The Harmos Horton Lusk team is led by directors Nathanael Starrenburg and Annie Steel and includes senior associate Matthew Wentz, associate Anthony Ellis and law clerk Tallara Daldorf.
